Press releases

Motions for summary judgment were granted in part and denied in part.

A live webcast and replay of the December 1 conference session will be available.

An existing licensing agreement with Angiotech Pharmaceuticals, Inc. allows Company to obtain an exclusive license for the use of paclitaxel and other agents in the coronary vascular field.

French government adds new patient categories to reimbursement approval criteria.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Equity investment in a privately held company developing a balloon-expandable, bioresorbable drug-eluting stent.

The two series of senior notes will have varied maturities and a combined aggregate principal amount of $500 million.

A live webcast and replay of the November 18 conference session will be available.

Company subsidiary will resume worldwide distribution after a voluntary recall of all unimplanted cochlear implant systems.

TAXUS™ Express2™ paclitaxel-eluting coronary stent system will be the subject of 15 presentations.

A live webcast and replay of the November 10 conference session will be available.

Patients with Gastroesophageal Reflux Disease (GERD) reported substantial improvements after the Enteryx® Procedure.

and Orlando, FL (November 2, 2004)-- Boston Scientific Corporation (NYSE: BSX) today announced results supporting the efficacy of the Enteryx Procedure in relieving the symptoms of...

and Orlando, FL (November 2, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from its ongoing Enteryx Procedure clinical trial for the treatment of...

Innovative uterine fibroid embolization (UFE) procedure is a less-invasive treatment option for fibroids.

Full line of mid-urethral sling products for the treatment of female stress urinary incontinence.

ARRIVE 2 registry program plans to enroll 5,000 patients at approximately 60 centers in the United States.

Repurchased shares will be made available for issuance under the Company's equity incentive plans and for general corporate purposes.

“This quarter was one of the best performances in our history," said Jim Tobin, President and CEO.

Company will launch the product immediately.

A live webcast and replay of the Tuesday, October 19 conference call will be available.

Registries studied more than 7,000 patients at 236 sites around the globe; results consistent with controlled TAXUS studies.

The results support early safety, which is consistent with results from previous TAXUS clinical trials.

Benefits reported at 12 months were maintained at two years.

The data demonstrated that the safety and efficacy benefits associated with the TAXUS stent system were maintained at two years.